drugset / Trial / NCT00756171

Colesevelam Versus Placebo in Cholestatic Pruritus

NCT00756171

Phase 2/3 Completed 38 enrolled Foundation for Liver Research
RandomizedParallel-groupQuadruple-blindTreatment

Summary

38 patients with pruritus due to chronic cholestatic liver disease will be evaluated in an investigator initiated, multicenter, double-blind, placebo-controlled, 3-week study assessing the effects of colesevelam on pruritus. Colesevelam is an oral, non-absorbable bile-acid sequestrant much more potent than cholestyramine but free of adverse effects. It is registered as a lipid lowering agent. The intensity of symptoms will be scored by means of daily Visual Analogue Scales (VAS). Fatigue, quality of life and cutaneous scratch lesions will also be evaluated using quantitative instruments.

Timeline

Start
2008-09
Primary completion
2009-05
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Colesevelam Other / unclassified 1875 mg Oral

Indications